These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20187247)

  • 1. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease.
    Petzinger GM; Fisher BE; Van Leeuwen JE; Vukovic M; Akopian G; Meshul CK; Holschneider DP; Nacca A; Walsh JP; Jakowec MW
    Mov Disord; 2010; 25 Suppl 1(0 1):S141-5. PubMed ID: 20187247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral biomarkers in exercise-induced neuroplasticity in Parkinson's disease.
    Mougeot JL; Hirsch MA; Stevens CB; Mougeot F
    Oral Dis; 2016 Nov; 22(8):745-753. PubMed ID: 26878123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic and cellular plasticity in Parkinson's disease.
    Chu HY
    Acta Pharmacol Sin; 2020 Apr; 41(4):447-452. PubMed ID: 32112041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional and compensatory synaptic plasticity in Parkinson's disease.
    Schroll H; Vitay J; Hamker FH
    Eur J Neurosci; 2014 Feb; 39(4):688-702. PubMed ID: 24313650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Roles of Microglia in the Basal Ganglia in Parkinson's Disease.
    Choudhury ME; Kigami Y; Tanaka J
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomy of the dopamine system in the basal ganglia.
    Smith Y; Kieval JZ
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S28-33. PubMed ID: 11052217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of function in Parkinson's disease: what's learning got to do with it?
    Beeler JA
    Brain Res; 2011 Nov; 1423():96-113. PubMed ID: 22000081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.
    Obeso JA; Rodriguez-Oroz M; Marin C; Alonso F; Zamarbide I; Lanciego JL; Rodriguez-Diaz M
    Neurology; 2004 Jan; 62(1 Suppl 1):S17-30. PubMed ID: 14718677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise and neuroplasticity in persons living with Parkinson's disease.
    Hirsch MA; Farley BG
    Eur J Phys Rehabil Med; 2009 Jun; 45(2):215-29. PubMed ID: 19532109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
    Gerlach M; Gsell W; Kornhuber J; Jellinger K; Krieger V; Pantucek F; Vock R; Riederer P
    Brain Res; 1996 Nov; 741(1-2):142-52. PubMed ID: 9001716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease.
    Milosevic L; Kalia SK; Hodaie M; Lozano AM; Fasano A; Popovic MR; Hutchison WD
    Brain; 2018 Jan; 141(1):177-190. PubMed ID: 29236966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parkinson's disease and cortico-Basal Ganglia circuits].
    Pan MK; Tai CH; Kuo CC
    Acta Neurol Taiwan; 2010 Sep; 19(3):213-22. PubMed ID: 20824544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projections from basal ganglia to tegmentum: a subcortical route for explaining the pathophysiology of Parkinson's disease signs?
    Delwaide PJ; Pepin JL; De Pasqua V; de Noordhout AM
    J Neurol; 2000 Apr; 247 Suppl 2():II75-81. PubMed ID: 10991670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untangling Basal Ganglia Network Dynamics and Function: Role of Dopamine Depletion and Inhibition Investigated in a Spiking Network Model.
    Lindahl M; Hellgren Kotaleski J
    eNeuro; 2016; 3(6):. PubMed ID: 28101525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data.
    Imbriani P; D'Angelo V; Platania P; Di Lazzaro G; Scalise S; Salimei C; El Atiallah I; Colona VL; Mercuri NB; Bonsi P; Pisani A; Schirinzi T; Martella G
    Parkinsonism Relat Disord; 2020 May; 74():57-63. PubMed ID: 32335490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of neuroplasticity in dopaminergic therapy for Parkinson disease.
    Zhuang X; Mazzoni P; Kang UJ
    Nat Rev Neurol; 2013 May; 9(5):248-56. PubMed ID: 23588357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.